Sweeney CJ et al., 2015-08-20: E3805/CHAARTED randomised 790 men starting androgen deprivation for newly metastatic hormone-sensitive prostate cancer to ADT plus six cycles of docetaxel or ADT alone. Median survival was 57.6 vs 44.0 months (HR 0.61), with the benefit concentrated in high-volume disease.
the median overall survival was 13.6 months longer with ADT plus docetaxel (combination therapy) than with ADT alone (57.6 months vs. 44.0 months; hazard ratio for death in the combination group, 0.61; 95% confidence interval [CI], 0.47 to 0.80; P<0.001).
Abstract (RESULTS)
Sweeney CJ et al., 2015-08-20: E3805/CHAARTED randomised 790 men starting androgen deprivation for newly metastatic hormone-sensitive prostate cancer to ADT plus six cycles of docetaxel or ADT alone. Median survival was 57.6 vs 44.0 months (HR 0.61), with the benefit concentrated in high-volume disease. Funder: 'Supported in part by a grant from the National Cancer Institute… Sanofi provided the docetaxel and a grant to ECOG-ACRIN.' Design/analysis: designed in 2005 by ECOG; coordinated by ECOG-ACRIN; the ECOG-ACRIN Statistical Center collected the data and was the data coordinating center – Sanofi did not run or analyse it. Conflicts: NEJM disclosure forms referenced, not printed. Maker: Sanofi (docetaxel). Comparator: ADT alone. Toxicity: grade 3-4 febrile neutropenia 6.2%, infection with neutropenia 2.3%, grade 3 sensory neuropathy 0.5%. Study type: randomized trial.
